DEVELOPMENT SAFETY UPDATE REPORT - ICH
The Development Safety Update Report (DSUR) proposed in this guideline is intended to be a common standard for periodic reporting on drugs under development (including
Download DEVELOPMENT SAFETY UPDATE REPORT - ICH
Information
Domain:
Source:
Link to this page:
Documents from same domain
ICH HARMONISED TRIPARTITE GUIDELINE
www.ich.orgGOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting
Final Concept Paper Q12: Technical and Regulatory ...
www.ich.orgFINAL Q12 Concept Paper Endorsed: 9 September 2014 -3- product lifecycle management. To date, the main emphasis has been on the implementation of
Q7 Implementation Working Group ICH Q7 …
www.ich.orgInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, P.O. Box 195, 1211 Geneva 20, Switzerland
GUIDELINE FOR GOOD CLINICAL PRACTICE
www.ich.orgGUIDELINE FOR GOOD CLINICAL PRACTICE INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the
ICH HARMONISED GUIDELINE
www.ich.orgE6(R1) Document History First Codification History Date New Codification November 2005 E6 Approval by the Steering Committee under Step 2 and release for public consultation.
ICH HARMONISED GUIDELINE - ICH Official web …
www.ich.orginternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised guideline guideline for elemental impurities
![[ICH E2F] [EXAMPLE DSUR – PHASE III …](/cache/preview/1/3/5/f/e/1/c/f/thumb-135fe1cf2cdb82799c462ad0ea089c48.jpg)
[ICH E2F] [EXAMPLE DSUR – PHASE III …
www.ich.orgfictional document for illustrative purposes only document date: 5 october 2010 [ich e2f] [example dsur – phase iii investigational drug] zb3579
ADDENDUM TO ICH E11: CLINICAL INVESTIGATION …
www.ich.org3 ICH HARMONISED GUIDELINE ADDENDUM TO ICH E11: CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION E11 (R1) ICH Consensus Guideline Released for Adoption on 18 August 2017, at Step 4 of the ICH
M4Q Implementation Working Group Questions & …
www.ich.org1. Introduction This document is intended to provide additional guidance for the preparation of an application file in the CTD-Q format (see section 2: General Issues).
I ADDENDUM TO ICH E6(R1 ... - ICH Official web site
www.ich.orgi ICH HARMONISED GUIDELINE INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE ICH E6(R2) Draft ICH Consensus Guideline Released for Consultation on 11 June 2015, at Step 2 of the ICH Process
Related documents
A Framework for Pharmacist Development in ... - …
www.codeg.orgAbout CoDEG The Competency Development and Evaluation Group (CoDEG) is a collaborative network of developers and researchers, practitioners, specialist …
Career Information : No points are allocated for ten …
www.dut.ac.zaCareer Information Bachelor of Health Sciences in Clinical Technology . Location . ML Sultan Campus (B Block 2 nd Floor) Purpose of the programme The purpose of this qualification is to develop a learner to possess
COMMITTEE FOR MEDICINAL PRODUCTS FOR …
www.ema.europa.euIt clarifies the requirements for clinical documentation for abridged applications for orally inhaled formulations and variations/extensions to a marketing authorisation, and including both single active substance products
Guideline on clinical development of fixed …
www.ema.europa.euThis is the nd2 revision of the guideline on clinical development of fixed combination medicinal products containing two or more active substances within a single pharmaceutical form.
GENERAL CLINICAL DOCUMENTATION AND …
www.himaa.org.auHIMAA Practice Brief 1 – General Documentation & Information Requirements 5 of 42 December 2006 V.1.0 4.0 GLOSSARY The following is a list of terms, associated definitions and concepts used in this
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comRegistration of Medicines Biosimilars . MEDICINES CONTROL COUNCIL. BIOSIMILAR MEDICINES QUALITY, NON-CLINICAL AND CLINICAL REQUIREMENTS
CLINICAL CONSIDERATIONS FOR EVALUATION OF …
www.who.intPage 4 of 8 2.4 Clinical development programme The applicant should provide in the PSF a tabulated summary of the clinical development programme, in one or more tables, in which critical parameters that may have changed
Related search queries
Development, CLINICAL, Requirements for clinical documentation for, Clinical development of fixed, Clinical development of fixed combination medicinal, CLINICAL DOCUMENTATION, Documentation, Requirements, MEDICINES CONTROL COUNCIL, CLINICAL REQUIREMENTS, CLINICAL CONSIDERATIONS FOR EVALUATION OF, Clinical development